243. Emerging Resistant Serotype 19A Streptococcus pneumoniae in Adults in the US
Session: Poster Abstract Session: Diagnostic Microbiology; Antimicrobial Sensitivities
Thursday, October 3, 2013
Room: The Moscone Center: Poster Hall C
Posters
  • Prevenar 13v_Isturiz_2013 IDWeek.pdf (609.5 kB)
  • Emerging Resistant Serotype 19A Streptococcus pneumoniae in Adults in the US

    RAUL E ISTURIZ, MD2, ROSALIND C HOLLINGSWORTH, PhD2, RODRIGO E MENDES, PhD1, ANDREW J COSTELLO1, DIAL HEWLETT, MD2, RONALD JONES, MD1

    1JMI Labs, N Liberty, IA

    2Pfizer Inc, Collegeville, PA

    Background: Serotype 19A S. pneumoniae (SPN) has emerged globally in children, and is the leading cause of invasive pneumococcal disease (IPD) in US adults. Concern exists about high prevalence, severe disease potential, and antimicrobial resistance. PCV7 was introduced in the US in 2000 and PCV13 (covering 19A) in 2010. This study determined prevalence and antimicrobial susceptibility of SPN 19A recovered from US adults

    Methods: 436 SPN 19A were identified from 2,636 SPN isolates from clinical specimens through the SENTRY Program in 28 States of the US during 2009-2011. Identification was performed by biochemical algorithms, susceptibility by MIC broth microdilution using CLSI methods (M07-A9, 2012) and interpretations (M100-S23, 2013), serotyping by cpsB sequencing, plus multiplex PCR

    Results: 19A was the most frequent serotype (436/2,636, 16.5%) in patients (174 female, 262 male) 18-91 years of age. Of the 436 isolates, 30 (6.9%) were invasive and 406 (93.1%) non-invasive. Applying CLSI specific criteria, 50.0% of invasive isolates and 8.6% of non-invasive isolates were susceptible to penicillin G. 49.8% of isolates were susceptible to ceftriaxone, 15.3% to erythromycin, 33% to clindamycin, 98.3% to levofloxacin and 12.8% to TMP-SMX. Only susceptibility to erythromycin tended to decrease in 2011

    Conclusion: Eleven years after introduction of PCV7 and around introduction of PCV13, 19A was the leading SPN serotype identified in this study of US adults. Resistance was high to β-lactams, macrolides and TMP-SMX, but not to fluoroquinolones, and remained stable overall. Follow up will be important to monitor the evolving incidence and resistance of serotype 19A after introduction and use of PCV13 in children and adults

    Raul E Isturiz, MD1, Rosalind C Hollingsworth1, Rodrigo E. Mendes, Ph.D.2, Andrew J Costello2, Dial Hewlett Jr., MD3 and Ronald Jones, MD4, (1)Pfizer Inc, Collegeville, PA, (2)Microbiology, JMI Laboratories, North Liberty, IA, (3)Pfizer, Inc., Collegeville, PA, (4)JMI Laboratories Inc, North Liberty, IA

    Disclosures:

    R. E. Isturiz, Pfizer Inc.: Employee, Salary

    R. C. Hollingsworth, Pfizer Inc.: Employee, Salary

    R. E. Mendes, JMI Laboratories: Employee, Salary

    A. J. Costello, JMI Laboratories: Employee, Salary

    D. Hewlett Jr., Pfizer Inc.: Employee, Salary

    R. Jones, JMI Laboratories: Employee, Salary

    Findings in the abstracts are embargoed until 12:01 a.m. PST, Oct. 2nd with the exception of research findings presented at the IDWeek press conferences.